Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of Radiation/Temozolomide and Immunotherapy With Daratumumab to Improve Antitumor Efficacy in Glioblastoma (PRIDE).

NCT04922723 is registered in ClinicalTrials.gov with West Virginia University as lead sponsor.

NCT NCT04922723
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04922723 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of Radiation/Temozolomide and Immunotherapy With Daratumumab to Improve Antitumor Efficacy in Glioblastoma (PRIDE).
Lead sponsor
West Virginia University
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
October 3, 2022
Completion date
December 31, 2026
Enrollment
16 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma